Following participation in a three-year international study of a new treatment for macular degeneration, Retina Health Center announces that the Food and Drug Administration (FDA) has approved the use of aflibercept (Eylea), also known as VEGF Trap-Eye, for "wet" age-related macular degeneration (AMD), the leading cause of blindness for people over 65. The disease occurs when new blood vessels grow beneath the retina and leak blood and fluid. This leakage causes blurriness, dark areas or distortion of the patient’s central vision. As an international test site for new macular degeneration therapies, Retina Health Center was a study site in the three-year clinical study of VEGF Trap-Eye the results of which were submitted to the FDA for review and approval. The results demonstrated that patients required fewer injections of VEGF Trap-Eye to achieve improvements in their vision.